Arch Therapeutics is a biotechnology company developing an innovative, elegant, and superior approach to the rapid cessation of bleeding (hemostasis) and control of fluid leakage (sealant) during surgery and trauma care.Arch intends to transform the landscape of interventional healthcare with products to seal and protect leaking and bleeding tissue. Arch’s solution elegantly controls the movement of these fluids and substances.The first product, AC5 Surgical Hemostatic Device, is designed to achieve hemostasis in minimally invasive (laparoscopic) and open surgical procedures and is intended to be regulated as a medical device. Surgeons would deem the product a “must have” because of its tremendous features, making it very different and far advanced compared to anything currently on the market. AC5 stops bleeding promptly. Unlike many competitive products, it conforms to irregular wound geometry, allows for normal healing, and helps maintain a clear field of vision directly into the wound area.